Special Company Pipeline

• Eli Lilly's Clinical Pipeline Selection

• Pfizer: “Future Biologics Powerhouse” and “The Emerging Oncology Leader”

• Esteve ( Spain )

Special Pipeline

• Cannabinoid-1 (CB1) receptor antagonists
  

• Two in-house lead clinical phase II projects with 2 nd generation antisense technology in diabetes and hypercholesterolemia;
• 1 st generation antisense product Alicaforsen enema available for partnering before phase III;
• IL-4 receptor targeting antisense and aerosol delivery for asthma and rhinitis in preclinical stage;
• Licensed antisense projects in clinical stages I and II mainly in oncology at OncoGenex, Lilly and Antisense Therapeutics;
• Phase I planned with c-raf kinase antisense for ocular disease at iCo Therapeutics

Pfizer: “Future Biologics Powerhouse” and “The Emerging Oncology Leader”

• Biologics' pipeline includes 11 projects of antibodies, proteins, peptides and oligonucleotides;
• CTLA4-antibody in melanoma with BLA filing target of 2007;
• Five antibodies in oncology pipeline;
• Oncology projects well balanced for phases

Esteve ( Spain )

• Late stage development projects mostly licensed-in with territorial rights in Europe ;
• Biologics' projects include antibody, protein and peptide;
• In-house drug discovery for small molecules;
• Proprietary lead project cizorlitine in phase II/III for urinary stress incontinence;
• Indication focus in research on CNS targets

Cannabinoid-1 (CB1) receptor antagonists

• First-in-class compound Acomplia (rimonabant) from Sanofi Aventis received approvable letter for obesity from FDA;
• FDA issued non-approvable for rimonabant in indication smoking cessation;
• Mainly used for treatment of obesity, but exploration for craving & addictive behaviour and for cognitive defects;
• Sanofi-Aventis dominating CB1 antagonist pipeline with back-ups;
• Three other companies with clinical stage CB1 antagonists;
• Further at least 8 companies with active R&D projects